Immutep Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial

Immutep (NASDAQ:IMMP) announced that the Database Safety Monitoring Board confirmed that the combination of eftilagimod alpha with pembrolizumab is safe and well tolerated at doses up to 30 mg per subcutaneous injection.

As quoted in the press release:

The patients eligible to participate in the TACTI-mel Phase I clinical trial are those that have either had a suboptimal response or had disease progression with pembrolizumab monotherapy. In this clinical trial, the combination starts at cycle five of pembrolizumab and is limited to six months of treatment.

Click here to read the full press release.